PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins

Background and Objectives: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy.

[1]  Alan A. Wilson,et al.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  M. Higuchi,et al.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α‐synuclein pathology , 2017, Movement disorders : official journal of the Movement Disorder Society.

[3]  Virginia M. Y. Lee,et al.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.

[4]  Hanna Cho,et al.  18F‐AV‐1451 binds to putamen in multiple system atrophy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[5]  Keith A. Johnson,et al.  Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies , 2017, Annals of neurology.

[6]  C. Rowe,et al.  Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy , 2017, European journal of neurology.

[7]  Hanna Cho,et al.  Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[8]  Anthony J. Spychalla,et al.  [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[9]  M. Schain,et al.  Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.

[10]  Martin J. McKeown,et al.  DCTN1 p.K56R in progressive supranuclear palsy. , 2016, Parkinsonism & related disorders.

[11]  H. Arai,et al.  Characteristics of Tau and Its Ligands in PET Imaging , 2016, Biomolecules.

[12]  U. Sengupta,et al.  Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies , 2015, Biological Psychiatry.

[13]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[14]  Ming-Rong Zhang,et al.  PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.

[15]  T. Hortobágyi,et al.  Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.

[16]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[17]  N. Wood,et al.  Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician , 2014, Movement disorders clinical practice.

[18]  A. Bonnet,et al.  DCTN1 mutation analysis in families with progressive supranuclear palsy-like phenotypes. , 2014, JAMA neurology.

[19]  D. Dickson,et al.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. , 2013, American journal of neurodegenerative disease.

[20]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[21]  J. Holton,et al.  The neuropathology, pathophysiology and genetics of multiple system atrophy , 2012, Neuropathology and applied neurobiology.

[22]  M. Farrer,et al.  Elucidating the genetics and pathology of Perry syndrome , 2010, Journal of the Neurological Sciences.

[23]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  A. Lees,et al.  Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. , 2007, Brain : a journal of neurology.

[25]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[26]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[27]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[28]  J. Trojanowski,et al.  Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.

[29]  K. Arima,et al.  NACP/α-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies , 2000, Acta Neuropathologica.

[30]  Kazuko Aoto,et al.  Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies , 1999, Brain Research.

[31]  D. Dickson.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[32]  Shigeo Hirai,et al.  NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.

[33]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[34]  I. Grundke‐Iqbal,et al.  Lewy Bodies Contain Epitopes Both Shared and Distinct from Alzheimer Neurofibrillary Tangles , 1988, Journal of neuropathology and experimental neurology.

[35]  D. Dickson,et al.  Autosomal dominant Parkinson's disease caused by SNCA duplications. , 2016, Parkinsonism & related disorders.

[36]  J. Trojanowski,et al.  Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. , 2002, Acta neuropathologica.

[37]  K. Arima,et al.  NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. , 2000, Acta neuropathologica.

[38]  K. Arima,et al.  NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. , 1998, Acta neuropathologica.

[39]  D. Selkoe,et al.  X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.